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Dear Colleague,
Paradigm strain exists in psychiatric
pharmacology. The prevailing monoamine-
based psychotropic agents have in some
circumstances saved lives, robustly benefitted
patient reported outcomes (e.g., quality of life
measures, functionality), and have facilitated
reintegration and recovery. Unfortunately,
these foregoing desirable outcomes are an
uncommon occurrence for most individuals
who receive existing treatments. For the
common and severe brain disorders (e.g.,
mood, anxiety, and psychotic disorders), the
insufficiency of extant treatments has provided
the impetus to evaluate the role of other
targets/systems. Moreover, there is consensus
that available psychotropic agents are not
‘‘disease-modifing’’ and are rather symptom
suppressing an/or providing only for
temporary adaptation.
The paradigm strain of the monoamine
hypotheses has resulted in a large number of
antidepressants and antipsychotics that are not
genuinely novel when compared to some of the
erstwhile psychotropics (e.g., tricyclic
antidepressants). It is however, incorrect to
conclude that all antidepressants and
antipsychotics are identical (they clearly are
not), as evidenced by their tolerability, efficacy,
and pharmacological profile. The business
model in CNS therapeutics has fostered a level
of complacency in drug discovery wherein,
until recently, the return on investment has
justified a maintenance of status quo.
The genericization of most psychotropic
medicine, the ‘‘patent cliff’’ experienced by
many blockbuster psychiatric medicines, and
the lack of reimbursement by public/private
payers has contributed to a lack of enthusiasm
for drug development for psychiatric disorders.
This foregoing confluence of factors could,
however, provide the impetus for a different
approach to drug discovery and development.
Going forward, psychiatry, and its granting
agencies, could do a much better job at
instantiating viable clinical targets for
psychiatric syndromes. Moreover, multilateral
partnerships in other therapeutic areas (e.g.,
HIV-AIDS) have resulted in not only genuinely
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novel and revolutionary treatments, but
treatments that are delivered in short time to
the principal stakeholder, i.e., the patient.
During the next 1–2 years, psychiatry will
continue to identify agents that are refinement
and evolution of existing agents. In some cases,
these agents may represent structural
optimization from an existing progenitor
molecule already in the clinical ecosystem.
Contemporaneous with these foregoing
developments are identification of agents with
novel targets (e.g., intranasal ketamine, agents
that target cellular bioenergetics/
inflammation). Moreover exploring the
pluripotentiality of stem cells seems an
exciting opportunity. Targeting many of the
foregoing molecular systems is conveniently
possible by repurposing some of the over
20,000 medicinal agents that are available
globally. Examples of this have been observed
in other therapeutic areas (e.g., the use of agents
primarily intended for oncology to treat
macular degeneration).
Where does that leave us? During the next
1–2 years, we will see new agents that have
unique effects on monoaminergic systems (e.g.,
vortioxetine, levomilnacipran). The pursuit of
mechanistically novel agents will be fuelled by
scientific, clinical, economic, and health
systems factors. It certainly has been identified
that a yawning chasm exists between
developments in neuroscience and genuinely
novel ‘‘neuro-glial’’ pharmacology. It is unlikely
that in 1–2 years the gap will witness a
significant narrowing; it is, however, not
unreasonable to expect the next 1–2 years to
provide an empirical edifice for public, private,
advocacy, and non-governmental organization
support for unique psychotropic agents that are
capable of modifying disease course.
I have found the developments in HIV-AIDS
treatment to be the closest metaphor and
inspiration for psychiatric therapeutics. On
June 5, 1981, the first case of HIV-AIDS was
identified in South Central Los Angeles. A year
ago, the Centers for Disease Control and
Prevention declared HIV-AIDS a chronic
disease. This highly stigmatized condition
which was a death sentence during the 1980s
and 1990s, has witnessed such remarkable
change in large part due to the openness to
explore viable targets supported by multilateral
partnership with an expectation of treatment
availability in the very near future rather than
some nebulous future date.
Psychiatry has not historically embraced
multilateral partnerships—at its peril. The
future, however, can look very bright if
psychiatry embraces a multilateral pursuit of
novel targets, provides bold leadership
intellectually, and there is sufficient reward for
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